Literature DB >> 30606476

Interleukin 4 inhibits high mobility group box-1 protein-mediated NLRP3 inflammasome formation by activating peroxisome proliferator-activated receptor-γ in astrocytes.

Xiaolong Yao1, Qian Jiang2, Wei Ding2, Pengjie Yue2, Junwen Wang2, Kai Zhao2, Huaqiu Zhang3.   

Abstract

High mobility group box-1 protein (HMGB-1) is one of the most important DAMPs and has been previously shown to promote the formation of the NOD-like receptor with pyrin domain containing-3 (NLRP3) inflammasome in microglia. Interleukin 4 (IL4) is a Th2-derived cytokine that plays a significant role in the function of various immune cells. However, the underlying molecular mechanism by which IL4 signaling antagonizes NLRP3 inflammasome is poorly characterized. In particular, whether IL4 could modulate NLRP3 inflammasome in astrocytes remains unknown. In the present study, we elucidated this phenomenon and the mechanism by which IL4 inhibits HMGB1-mediated NLRP3 inflammasome formation in astrocytes. For this purpose, we cultured and extracted primary astrocytes, setup different concentrations of HMGB1, and used immunofluorescence and western blotting to detect NLRP3 inflammasome formation, including NLRP3, ASC and caspase-1, and signaling changes in the nuclear factor κB (NF-κB). Meanwhile, BAY 11-7082 and IL4 were added with HMGB1 to observe the NLRP3 inflammasome and changes in NF-κB expression. Our data showed that HMGB1 could effectively promote NLRP3 inflammasome formation by activating NF-κB in astrocytes. This effect can be inhibited by BAY 11-7082, a NF-κB inhibitor. Meanwhile, IL4 could activate PPARγ via the STAT6 singling pathway and inhibit NF-κB activation, significantly decreasing formation of the NLRP3 inflammasome complex. Our study demonstrated that the NLRP3 inflammasome complex is also expressed in astrocytes, and IL4 could inhibit HMGB1-mediated NLRP3 inflammasome formation, through negative regulation of NF-κB activity and promotion of PPARγ activation.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Astrocyte; HMGB1; IL4; NF-κB; NLRP3 inflammasome; PPARγ

Mesh:

Substances:

Year:  2018        PMID: 30606476     DOI: 10.1016/j.bbrc.2018.11.145

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

Review 1.  Exosomes and cancer: from molecular mechanisms to clinical applications.

Authors:  Ameneh Jafari; Amirhesam Babajani; Meghdad Abdollahpour-Alitappeh; Nayebali Ahmadi; Mostafa Rezaei-Tavirani
Journal:  Med Oncol       Date:  2021-03-20       Impact factor: 3.064

Review 2.  Glial Cells and Brain Diseases: Inflammasomes as Relevant Pathological Entities.

Authors:  Esperanza Mata-Martínez; Mauricio Díaz-Muñoz; Francisco G Vázquez-Cuevas
Journal:  Front Cell Neurosci       Date:  2022-06-16       Impact factor: 6.147

Review 3.  Role of the NLRP3 Inflammasome in Preeclampsia.

Authors:  Koumei Shirasuna; Tadayoshi Karasawa; Masafumi Takahashi
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-25       Impact factor: 5.555

Review 4.  Nuclear Receptors in the Control of the NLRP3 Inflammasome Pathway.

Authors:  Hélène Duez; Benoit Pourcet
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-25       Impact factor: 5.555

5.  The loss of microglia activities facilitates glaucoma progression in association with CYP1B1 gene mutation (p.Gly61Glu).

Authors:  Amani Alghamdi; Wadha Aldossary; Sarah Albahkali; Batoul Alotaibi; Bahauddeen M Alrfaei
Journal:  PLoS One       Date:  2020-11-10       Impact factor: 3.240

6.  High mobility group box-1 levels in schizophrenia: Potential biomarker of remission phase.

Authors:  Nuryil Yilmaz; Zekeriya Yelboga; Yavuz Yilmaz; Ozlem Demirpence
Journal:  J Med Biochem       Date:  2021-06-05       Impact factor: 3.402

Review 7.  Immune Cells in the BBB Disruption After Acute Ischemic Stroke: Targets for Immune Therapy?

Authors:  Yan-Mei Qiu; Chun-Lin Zhang; An-Qi Chen; Hai-Ling Wang; Yi-Fan Zhou; Ya-Nan Li; Bo Hu
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.